C12Y 306/03009
Na+/k+-exchanging atpase
Official title: Na+/K+-exchanging ATPase (3.6.3.9)
C12Y306/03009 (Na+/k+-exchanging atpase) appears on 14 US grants and 24 published applications in this corpus.
Search patents in C12Y- Granted patents
- 14
- Published applications
- 24
- Assignees
- 13
- Inventors
- 42
- Latest grant
- 9 Jan 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 2 | 2 |
| 2010 | 0 | 3 |
| 2011 | 1 | 1 |
| 2012 | 1 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 1 | 3 |
| 2016 | 0 | 1 |
| 2017 | 1 | 2 |
| 2018 | 0 | 1 |
| 2019 | 1 | 0 |
| 2020 | 1 | 4 |
| 2021 | 2 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
By publication year.
Recent patents
- Compositions and methods for treatment of uremic cardiomyopathy9 Jan 2024US 11,865,162 B2Marshall University Research Corporation
- Methods for treating obesity26 Apr 2022US 11,311,600 B2Marshall University Research Corporation
- Diagnosis of a neurological disease7 Sep 2021US 11,112,407 B2EUROIMMUN Medizinische Labordiagnostika AG
- Compositions and methods for treating retinopathy13 Apr 2021US 10,973,867 B2Marshall University Research Corporation
- Cardiotonic steroid antagonists and related methods22 Sep 2020US 10,781,431 B2Marshall University Research Corporation
- Expression vectors and related methods of delivery of na/k atpase/src receptor complex antagonists21 May 2020US 2020/0157568 A1
- Pancreatic cancer targets and uses thereof16 Apr 2020US 2020/0116726 A1Celera Corporation
- Compositions and methods for treatment of uremic cardiomyopathy19 Mar 2020US 2020/0085918 A1Marshall University Research Corporation
- Compositions and methods for treating retinopathy30 Jan 2020US 2020/0030404 A1Marshall University Research Corporation
- Methods for treating obesity13 Dec 2018US 2018/0353569 A1Marshall University Research Corporation
Most cited
By later US patents
- Pancreatic cancer targets and uses thereof104US 7,473,531 B1Colora Corporation · 2009
- RNAi-mediated inhibition of ocular targets15US 7,592,324 B2Alcon Inc. · 2009
- Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases7US 8,283,441 B2The University of Toledo · 2012
- Diagnosis of a neurological disease2US 11,112,407 B2EUROIMMUN Medizinische Labordiagnostika AG · 2021
- Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same2US 7,888,059 B2Yeda Research and Development Co. Ltd. · 2011